Valuation: Denali Therapeutics Inc.

Market Cap 2.94B 2.63B 2.43B 2.2B 4.12B 279B 4.18B 29.21B 11.57B 146B 11.04B 10.81B 461B P/E 2026 *
-8.09x
P/E 2027 * -7.98x
Enterprise Value 2.23B 2B 1.84B 1.67B 3.13B 212B 3.18B 22.18B 8.78B 111B 8.39B 8.21B 350B EV / Sales 2026 *
44.1x
EV / Sales 2027 * 16.8x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-1.34%
1 week+4.54%
Current month-10.93%
1 month-9.71%
3 months-20.34%
6 months-7.35%
Current year+11.51%
1 week 17.94
Extreme 17.945
19.35
1 month 17.33
Extreme 17.33
21.26
Current year 15.34
Extreme 15.34
27.3
1 year 13.75
Extreme 13.75
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.08
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 2022-04-30
Chief Executive Officer 50 2015-07-31
Chief Tech/Sci/R&D Officer 58 2025-11-05
Director TitleAgeSince
Director/Board Member 50 2015-02-28
Director/Board Member 73 2015-03-31
Director/Board Member 68 2015-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 Sell

Chief Technology Officer

-1,654 0.0010%
9/2/26 Sell

Director

-11,439 0.0072%
9/1/26 Sell

Founder

-2,768 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%+4.54%+15.35%-6.26% 2.94B
+2.41%+0.29%+39.41%+73.38% 64.69B
-0.15%+7.50%+11.42%+75.22% 54.78B
+0.57%+4.60%+7.71%+100.57% 53.49B
+0.37%+4.67%+26.68%+54.16% 45.98B
-1.21%+2.32%+21.50%+126.83% 42.94B
-0.37%+5.07%+243.23%+834.48% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
-0.87%-9.29%+21.78%+2.02% 23.97B
-0.38%+5.68%+38.39%+29.86% 23.67B
Average -0.09%+2.63%+44.35%+133.88% 38.61B
Weighted average by Cap. +0.25%+2.74%+45.50%+150.21%

Financials

2026 *2027 *
Net sales 50.65M 45.23M 41.79M 37.87M 70.84M 4.81B 72.02M 503M 199M 2.52B 190M 186M 7.94B 131M 117M 108M 97.67M 183M 12.4B 186M 1.3B 513M 6.5B 490M 480M 20.48B
Net income -445M -397M -367M -333M -622M -42.23B -632M -4.42B -1.75B -22.12B -1.67B -1.63B -69.75B -451M -403M -372M -337M -631M -42.79B -641M -4.48B -1.77B -22.42B -1.69B -1.66B -70.69B
Net Debt -708M -633M -584M -530M -991M -67.25B -1.01B -7.03B -2.78B -35.23B -2.66B -2.6B -111B -749M -669M -618M -560M -1.05B -71.07B -1.06B -7.43B -2.94B -37.24B -2.81B -2.75B -117B
Projected Income Statement - Annual - Denali Therapeutics Inc.
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
26-10-23 US$18.41 -1.34% 1,005,558
26-10-22 US$18.66 -0.11% 816,745
26-10-21 US$18.68 -1.32% 1,429,264
26-10-20 US$18.93 +4.93% 1,824,103
26-10-19 US$18.04 +2.44% 2,688,860
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Denali Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
18.41USD
Average target price
35.50USD
Spread / Average Target
+92.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Denali Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. DNLI Stock